HR-positive/HER2-negative breast cancer arising in patients with or without <i>BRCA2</i> mutation: different biological phenotype and similar prognosis.

In multivariate analyses (adjusted for tumour size, lymph nodes, grade, HR status, vascular invasion, the surgical approach for primary tumours, neoadjuvant chemotherapy and BRCA2 mutation), BRCA2 mutation breast cancers showed a similar DRFS compared to non-mutation breast cancers, although this did not reach statistical significance (hazard ratio = 1.09, 95% CI = 0.61–1.93, p = 0.76) ( Table 4 ).

also in 111,027 other papers